WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.
Status: | Completed |
---|---|
Conditions: | HIV / AIDS |
Therapuetic Areas: | Immunology / Infectious Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/21/2016 |
Start Date: | August 2005 |
End Date: | July 2006 |
An Open-label Study of the Tolerability of a Subcutaneous Needle-free Injection Device Used to Administer Fuzeon, Compared With the Standard Needle/Syringe Supplied With Commercial Fuzeon in HIV-1 Infected, ARV Treatment-experienced Adults
The purpose of this study is to evaluate the tolerability of a subcutaneous needle-free
injection device used to administer Fuzeon, compared with the standard needle/syringe
supplied with commercial Fuzeon. The anticipated time on study treatment is <3 months, and
the target sample size is <100 individuals.
injection device used to administer Fuzeon, compared with the standard needle/syringe
supplied with commercial Fuzeon. The anticipated time on study treatment is <3 months, and
the target sample size is <100 individuals.
Inclusion Criteria:
- male or female patients, >=18 years of age with HIV-1 infection;
- previously treated with antiretroviral agents.
Exclusion Criteria:
- prior use of Fuzeon or T-1249;
- inability to self-inject;
- active, untreated opportunistic infection.
We found this trial at
14
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials